“Hemophilia A Market” report has been added to DelveInsight
Hemophilia A Disease Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII.
Get Free Sample Copy Now- https://www.delveinsight.com/sample-request/hemophilia-a2030-market
Hemophilia A Regions Covered
Hemophilia A Market Companies
Hemophilia A Drugs
Hemophilia A Treatment Market
The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.
Hemophilia A Market Report
About 30% of severe hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NovoSeven, FEIBA).
Hemophilia A Market Research
As per DelveInsight estimation, the future of hemophilia treatment is continuing to trend toward extended half-life therapies as well as more novel approaches including siRNA, bi-specific antibodies and gene therapy. If these therapies are ultimately successfully commercialized they have the potential to transform the current standard of care for hemophilia A patients
Hemophilia A Market Industry
Hemophilia A is a life-long condition. Currently, there is no cure, but researchers are actively engaged in finding the cure through gene therapy. One hope is that by inserting a healthy version of the defective blood factor gene, a person with hemophilia will be able to produce reasonable amounts of a factor on their own.
Hemophilia A Market Trends
Generally, Hemophilia A patients are provided with “On Demand” and “Prophylaxis” treatment. But Prophylaxis treatment option has gained importance in comparison to the on-demand treatment options. Currently, the major treatment options of Hemophilia A are:
Currently, the major treatment options of Hemophilia A are Factor Replacement Concentrates, the source of which is either recombinant DNA technology or Human plasma-derive, and Bypassing agents. Moreover, this is an off-label treatment option, wherein Desmopressin Acetate (DDAVP) and Adjunctive therapies are also available for the management of Hemophilia A.
Hemophilia A Market Highlights
Table of content
1. Key Insights
2. Executive Summary of Hemophilia A
3. Competitive Intelligence Analysis for Hemophilia A
4. Hemophilia A: Market Overview at a Glance
5. Hemophilia A: Disease Background and Overview
6. Patient Journey
7. Hemophilia A Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Hemophilia A Treatment
11. Marketed Products
12. Emerging Therapies
13. Hemophilia A: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Hemophilia A
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/